Name of this trial: ONO-0530-03-001 (INTREPID)
What type of cancer is this for? Polycythemia Vera
Who is this trial for? Patients with phlebotomy dependent polycythemia vera
What biomarkers are involved? JAK2 Mutation
What is the National Clinical Trial #? NCT07429266; https://clinicaltrials.gov/study/NCT07429266
Brief summary of this trial: A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera
Need to know: Must have a diagnosis of PV and have a JAK2 mutation confirmed by pathology report of a blood or bone marrow sample analyzed by polymerase chain reaction or sequencing that shows either the most common JAK2 V617F mutation or a mutation in exons 12 to 15. Must not have had prior treatment of PV with transmembrane serine protease 6 inhibitors (including sapablursen) or hepcidin mimetics.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@thechc.com